2. Cell Cycle/DNA Damage Immunology/Inflammation
  3. Checkpoint Kinase (Chk) IFNAR
  4. Monalizumab

Monalizumab  (Synonyms: IPH2201)

Cat. No.: HY-P99032 Purity: 99.69%
COA
SDS
Technical Support

Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

For research use only. We do not sell to patients.

CAS No. : 1228763-95-8

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Monalizumab Featured Recommendations:

Monalizumab Related Antibodies

Top Publications Citing Use of Products

    Monalizumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Nov 28;16(1):865.  [Abstract]

    Healthy donor PBMCs were co-cultured with SKO-007 (J3) target cells, either untreated or treated with the indicated inhibitors for 48 h. NK cell degranulation assay was conducted at an Effector/Target (E/T) ratio of 2.5:1 in complete medium at 37 °C and 5% CO2 for 2 h. To assess the role of the NKG2A or KIR receptors, NK cells pretreated with blocking mAbs for NKG2A (Monalizumab,15 min) or IgG control were incubated with Pol I inhibitor-treated target cells.

    Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069.

    Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks). Body weights and tumor volumes were measured twice a week from the seventh day after injection of cancer cells.

    Monalizumab purchased from MedChemExpress. Usage Cited in: Carcinogenesis. 2025 Oct 22:bgaf069.

    Plasma perforin concentrations were determined by ELISA. The results showed that Monalizumab (MNZ) (300 μg/100 μL/mouse; i.p.; once a week for five consecutive weeks) treatment significantly increased perforin levels, which were lower in RT-R-MDA-MB-231-injected mice than in MDA-MB-231-injected mice.

    Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410.  [Abstract]

    Degranulation of NKG2A+ KIR− NK cells after 4 hours of co-culture with untreated or 12 hours IFNγ-pretreated WT or HLA-E KO A375 cells in the presence of 5 µg/mL IgG1 or Monalizumab (mona) mAb (n=6).

    Monalizumab purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Jul 1; 12(7): e009410.  [Abstract]

    Reduction in B2M KO cell population after 24 hours of co-culture of NK cells with mixed WT:B2M KO cells (1:1) at different E:T ratios in the presence of 5 µg/mL of indicated mAbs (Monalizumab (mona), etc.).

    Monalizumab purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Jan 8;42(1):135-156.e17.  [Abstract]

    Flow cytometry panels demonstrating the expression level of NKG2A⁺, PD-1⁺Tim-3⁺, Granzyme B⁺ and IFN-γ⁺ in CD8⁺ tumor infiltrating T cells co-cultured with HLA-E⁺ tumor infiltrating B cells, either treated without Monalizumab (upper panel) or with Monalizumab (100 mg/mL; 20 h) (bottom panel).

    View All Checkpoint Kinase (Chk) Isoform Specific Products:

    View All Isoforms
    Chk1 Chk2 BUBR1

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC)[1][2].

    Isotype

    Human IgG4 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    NKG2A/CD94
    In Vitro

    Monalizumab blocks NKG2A and enhances CLL NK-cell mediated cytotoxicity against HLA-E-expressing K562 cells[3].
    Monalizumab enhances the Enzalutamide (HY-70002) (10 μM)-induced NK cell activation and killing of prostate cancer cells (LNCaP and 22Rv1)[5].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Monalizumab Related Antibodies
    In Vivo

    Monalizumab (50  μg, intratumoral injections, together with 8 millions of activated NK cells) effectively inhibits tumor growth in xenografted HLA-E+ tumors in immunodeficient mice[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell[4]
    Dosage: 50 μg, together with 8 millions of activated NK cells
    Administration: intratumoral injections
    Result: Shows a synergestic antitumor effect.
    Enhanced NK-cell killing, and induces lysis of tumor cells.
    Clinical Trial
    Gene ID

    3821  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Molecular Weight

    146.3 kDa

    CAS No.
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Monalizumab]
    Shipping

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG4 kappa
    Biological Activity
    • Immobilized NKG2A-CD94 Heterodimer Protein, Human (HEK293, His-Flag, HY-P70713) can bind Monalizumab. The EC50 for this effect is 4.83 ng/mL.
    Purity & Documentation

    Purity: 99.69%

    SDS (251 KB)

    COA (232 KB) SDS-PAGE (74 KB) SEC-HPLC (182 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Monalizumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Monalizumab1228763-95-8IPH2201IPH 2201IPH-2201Checkpoint Kinase (Chk)IFNARInterferon-α/β receptorInterferon-alpha/beta receptorCancer immunotherapyCD8 T cellsNK cellsNKG2AInhibitory immune receptorHLA-E/Qa-1head and neck squamous cell carcinomacancer immunotherapyimmune checkpoint inhibitorsrecurrent or metastaticInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Monalizumab
    Cat. No.:
    HY-P99032
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.